|
|
DSpace at RU >
University Library >
Academic bibliography >
Files in This Item:
| File |
Description |
Size | Format |
| publisher's version | 361.92 kB | Adobe PDF | Under Embargo
|
|
| Title: | Arts syndrome is caused by loss-of-function mutations in PRPS1 |
| Author(s): | Brouwer, A.P.M. de (236446894) Williams, K.L. Duley, J.A. Kuilenburg, A.B.P. van Nabuurs, S.B. (291535941) Egmont-Peterson, M. (298983133) Lugtenberg, D. (29897987X) Zoetekouw, L. Banning, M.J.G. (314085610) Roeffen, M. Hamel, B.C.J. (079063632) Weaving, L. Ouvrier, R.A. Donald, J.A. Wevers, R.A. (068311508) Christodoulou, J. Bokhoven, J.H.L.M. van (11529077X) |
| Publication year: | 2007 |
| Document type: | Article / Letter to editor |
| Journal: | American journal of human genetics |
| ISSN: | 0002-9297 |
| Volume: | vol. 81 |
| Issue: | iss. 3 |
| Start page: | p. 507 |
| End page: | p. 518 |
| Abstract: | Arts syndrome is an X-linked disorder characterized by mental retardation, early-onset hypotonia, ataxia, delayed motor development, hearing impairment, and optic atrophy. Linkage analysis in a Dutch family and an Australian family suggested that the candidate gene maps to Xq22.1-q24. Oligonucleotide microarray expression profiling of fibroblasts from two probands of the Dutch family revealed reduced expression levels of the phosphoribosyl pyrophosphate synthetase 1 gene (PRPS1). Subsequent sequencing of PRPS1 led to the identification of two different missense mutations, c.455T-->C (p.L152P) in the Dutch family and c.398A-->C (p.Q133P) in the Australian family. Both mutations result in a loss of phosphoribosyl pyrophosphate synthetase 1 activity, as was shown in silico by molecular modeling and was shown in vitro by phosphoribosyl pyrophosphate synthetase activity assays in erythrocytes and fibroblasts from patients. This is in contrast to the gain-of-function mutations in PRPS1 that were identified previously in PRPS-related gout. The loss-of-function mutations of PRPS1 likely result in impaired purine biosynthesis, which is supported by the undetectable hypoxanthine in urine and the reduced uric acid levels in serum from patients. To replenish low levels of purines, treatment with S-adenosylmethionine theoretically could have therapeutic efficacy, and a clinical trial involving the two affected Australian brothers is currently underway. |
| Subject: | UMCN 3.1: Neuromuscular development and genetic disorders UMCN 5.1: Genetic defects of metabolism |
| Organization: | Human Genetics UMCN Extern Bioinformatics Neurology |
| Appears in Collections: | Academic bibliography
|
|
Please use this identifier to cite or link to this item:
http://hdl.handle.net/2066/35096
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.
|
|